Nevro price target lowered to $14 from $17 at Wells Fargo

Wells Fargo lowered the firm’s price target on Nevro to $14 from $17 and keeps an Equal Weight rating on the shares following a change in analysts. The firm is less optimistic about a strong recovery in the core spinal cord stimulation market and sees potential competitive and reimbursement headwinds to Nevro’s growth.